The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Outcomes from the EPCORE DLBCL-3 trial: fixed-duration epcoritamab in elderly patients with DLBCL
Umberto Vitolo, MD, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy, shares insight into the EPCORE DLBCL-3 (NCT05660967) trial evaluating fixed-duration epcoritamab monotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Prof. Vitolo highlights favorable efficacy outcomes and indicates that a chemo-free approach may be feasible for elderly patients; however, longer-term follow-up is required. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
